# A Study to Evaluate the Efficacy and Safety of RSS0343 Tablets in Patients With Chronic Obstructive Pulmonary Disease

> **NCT07349524** · PHASE2 · RECRUITING · sponsor: **Reistone Biopharma Company Limited** · enrollment: 237 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** RSS0343 tablets
- **DRUG:** RSS0343 tablets Placebo

## Key facts

- **NCT ID:** NCT07349524
- **Lead sponsor:** Reistone Biopharma Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-10
- **Primary completion:** 2028-03
- **Final completion:** 2028-04
- **Target enrollment:** 237 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07349524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07349524, "A Study to Evaluate the Efficacy and Safety of RSS0343 Tablets in Patients With Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07349524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*